DOCT vs XJAN
FT Vest US Equity Deep Buffer ETF - October vs FT Vest US Equity Enhance & Moderate Buffer ETF - January
Which is better, DOCT or XJAN?
DOCT has been ahead.
DOCT led over 1Y and the full window. The two have moved almost in lockstep, correlation 0.92.
MarketXLS is not an investment adviser. This comparison is generated automatically from market data and is for information only. A Best mark means the better reading on that one measure, not a recommendation to buy.
Side-by-Side Comparison
| Metric | DOCT | XJAN |
|---|---|---|
| Expense Ratio | 0.85%Tie | 0.85%Tie |
| AUM | $402M | $71M |
| Dividend Yield | 0.00% | 0.00% |
| Holdings | 10 | 12 |
| YTD Return | +8.89%Best | +7.00% |
| 1Y Return | +11.21%Best | +9.59% |
| 3Y Return (annualized) | +10.88% | - |
| 5Y Return (annualized) | +8.29% | - |
| Volatility (annualized) | 5.7% | 4.3%Best |
| Max Drawdown | -9.9%Best | -10.0% |
| $10,000 over 2.7 years | $13,101Best | $12,717 |
| Fund Family | First Trust Portfolios (US) | First Trust Portfolios (US) |
| Category | Alternative | Alternative |
| Style | Option Writing | Option Writing |
| Inception | Oct 16, 2020 | Jan 22, 2024 |
Not shown on this pair: Top 10 Weight.
Volatility and max drawdown, and the $10,000 over 2.7 years row, are measured over the window both funds cover: Jan 22, 2024 to Oct 14, 2026 (2.7 years).
DOCT vs XJAN growth
Month-end closes. Both lines start at 0% in the first month shown, so the gap between them is the difference in growth across that window. The full view covers the 2.7 years both funds cover.
DOCT vs XJAN Performance
FT Vest US Equity Deep Buffer ETF - October (DOCT) is an ETF from First Trust Portfolios (US) and FT Vest US Equity Enhance & Moderate Buffer ETF - January (XJAN) is an ETF from First Trust Portfolios (US). Over the past year DOCT returned +11.21% while XJAN returned +9.59%. Year to date, DOCT is up 8.89% versus a gain of 7.00% for XJAN.
Past performance does not guarantee future results.
Risk: Volatility and Drawdowns
DOCT has been the more volatile fund, with annualized monthly volatility of 5.7% compared with 4.3% for XJAN. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -9.9% for DOCT and -10.0% for XJAN. Drawdown depth is what each fund did in the worst stretch of the window measured above.
The two funds' monthly returns correlate at 0.92. They move almost in lockstep, so holding both mostly duplicates the same exposure.
Fees and Cost Over Time
DOCT charges 0.85% per year while XJAN charges 0.85%. On a $10,000 position that is $85 vs $85 annually. On income, DOCT currently yields 0.00% against 0.00% for XJAN.
You are not choosing between two funds in isolation.
Whichever of DOCT and XJAN you pick has to sit alongside everything else you own. Add the rest and see what the combination actually holds.
Free for up to 10 holdings. No account needed.
Frequently Asked Questions
Which is cheaper, DOCT or XJAN?
DOCT has an expense ratio of 0.85% while XJAN charges 0.85%. At the precision these are quoted to, they cost the same.
Which performed better, DOCT or XJAN?
Over the past year DOCT returned +11.21% vs +9.59% for XJAN, so DOCT leads on 1-year performance. Past performance does not guarantee future results. This is information, not a recommendation.
Which is riskier, DOCT or XJAN?
DOCT has been the more volatile fund at 5.7% annualized versus 4.3% for XJAN. Worst drawdown: DOCT -9.9% vs XJAN -10.0%.
Should I hold both DOCT and XJAN?
DOCT and XJAN have a monthly-return correlation of 0.92, so they move almost identically. What is left to separate them is the fee and the index each one tracks. This is information, not a recommendation.
Which pays a higher dividend, DOCT or XJAN?
DOCT yields 0.00% while XJAN yields 0.00%, so XJAN currently pays the higher dividend yield.
Is XJAN better than DOCT?
DOCT led over 1Y and the full window. The two have moved almost in lockstep, correlation 0.92. Which one suits a particular account depends on what it is for. This is information, not a recommendation.